Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | QDPR | P09417 | 2/20 | 0.35 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 3/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18866160 | 0.91 | RAB9A (0.38) | ALDH1A1HPGDPOLBHTTGAA | |
| SCHEMBL20473440 | 0.87 | L3MBTL3 (0.45) | ALDH1A1KDM4EPOLBL3MBTL1 | |
| SCHEMBL5360848 | 0.86 | SLC18A3 (0.40) | ALDH1A1KDM4EHPGDNPSR1HSD17B10 | |
| SCHEMBL27148523 | 0.83 | MGLL (0.33) | HTR2BMGLL | |
| SCHEMBL21382261 | 0.82 | HTT (0.47) | KDM4EHPGDNPSR1HSD17B10MEN1 | |
| SCHEMBL30726003 | 0.80 | PDE4B (0.43) | — | |
| SCHEMBL29774649 | 0.79 | NAMPT (0.40) | ALDH1A1KDM4EHPGDNPSR1 | |
| SCHEMBL1608843 | 0.76 | — | — | |
| SCHEMBL23062943 | 0.75 | CHRNA7 (0.30) | — | |
| SCHEMBL27628276 | 0.75 | HTT (0.35) | ALDH1A1KDM4EHPGDNPSR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230148194-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-11 | — | — | US | disclosed |
| US-20230117324-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2023-04-20 | — | — | US | disclosed |
| EP-3768684-B1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN LA ROCHE (CH) | 2023-02-22 | — | — | EP | disclosed |
| EP-3953332-A1 | TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS | C4 Therapeutics, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| WO-2020210630-A1 | TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS | C4 THERAPEUTICS, INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| US-10428034-B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors | PFIZER INC. (US) | 2019-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230148194-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | DGKK, DGKG, DGKA | ALDH1A1 3915/4885KDM4E 1315/4885HPGD 1407/4885 |
| US-20230117324-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | MGLL, LPL, LIPC | ALDH1A1 1432/4885KDM4E 1888/4885HPGD 2925/4885 |
| US-10428034-B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors | MAG, PYM1, HIF1AN | ALDH1A1 471/4885KDM4E 1858/4885HPGD 937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.